… effectiveness and toxicity compared with gefitinib for the … of randomized controlled trials
from the Cochrane network was evaluated in terms of the presence or absence of a randomized …

… results in longer progression-free survival with less toxicity than gefitinib alone. A total of 70
… gefitinib alone in patients with NSCLC [17]. In this study, we aim to assess whether gefitinib …

… Toxicity Criteria; EHT = elevated hepatic transminases; * indicates that grade 3/4 toxicities
only occurred in patients receiving gefitinib … clinical trials evaluating the efficacy of gefitinib in …

… , we had been able to administer gefitinib in doses as high as … toxicities that were observed
in previous phase I studies [17]. … clinical trials for leptomeningeal metastasis, this trial defined …

… effects of gefitinib are readily reversible on withdrawal of the compound. Both preclinical
and early clinical studies indicate that the toxicities associated with gefitinib are minimal (12). …

… This study was conducted to assess the efficacy and toxicity of gefitinib as first line treatment
in … be compared with standard treatment, and be verified by larger-specimen clinical trials. …

… II trials of gefitinib monotherapy in patients with recurrent non-small cell lung cancer. Clinical
trials are … patients then receive gefitinib until disease progression or intolerable toxicity. …

… was started, there was a strong rationale to evaluate in a clinical study the … study with the
combination of gefitinib and FOLFIRI, we observed disappointing results in terms of toxicity, very …

… 3 toxicities in 6 gefitinib patients and 3 grade 3 toxicities (1 … Because of pre-clinical data
suggesting that EGFR may drive … patients in phase II clinical trials of gefitinib and erlotinib for …

… received gefitinib 250 mg per day orally until disease progression or unacceptable toxicity
… Patients were considered evaluable if they received at least one dose of gefitinib and had …